Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00236-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsmi=282213984&_hsenc=p2ANqtz--lPQbhCj-umufCoDjb20fSMVi-Da7u0az0c0B1GrlEbWxf_Vf6h1GIgb57rep0nOHYLAX_2n__YDiRO4fYSRKA41M5pw&utm_content=282054549&utm_source=hs_email